Calidi Biotherapeutics Inc. to Showcase RedTail Platform and Oncology Advancements in Investor Webinar

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company at the forefront of developing targeted genetic medicine therapies, is set to host an investor webinar on July 24, 2025, at 4:15 p.m. ET. The webinar, led by CEO Eric Poma, Ph.D., aims to spotlight the company's innovative RedTail(TM) platform. This platform represents a significant leap forward in the treatment of metastatic tumors, utilizing a systemically delivered viral therapy designed to evade immune detection, thereby offering a novel approach to cancer treatment.

During the webinar, Calidi Biotherapeutics will present preclinical data on its lead candidate, CLD-401, which has demonstrated promising results in tumor elimination and the activation of immune memory. These findings underscore the potential of the RedTail platform to revolutionize oncology treatment by addressing some of the most challenging aspects of cancer therapy. The company is currently advancing toward an Investigational New Drug (IND) filing, a critical step in bringing its therapies to patients, and is actively seeking strategic pharmaceutical partnerships to support the commercialization of its technologies.

The investor webinar will not only provide an in-depth look at Calidi Biotherapeutics' groundbreaking work but also include a Q&A session, offering participants the opportunity to engage directly with the company's leadership. This event is a testament to Calidi's commitment to transparency and its dedication to advancing cancer treatment through innovative research and development. For those interested in learning more about Calidi Biotherapeutics and its pioneering work in immuno-oncology, additional information is available at https://www.calidibio.com.